Dermal Fillers Market Size, Share & COVID-19 Impact Analysis, By Material (Hyaluronic Acid, Calcium Hydroxylapatite, Poly-L-lactic Acid, PMMA (Poly (Methyl Methacrylate)), Fat Fillers, and Others), By Product (Biodegradable and Non-Biodegradable), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration of Volume/Fullness, and Others), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2023-2030

The global dermal fillers market size was valued at USD 5.01 billion in 2022 and is projected to grow from USD 5.32 billion in 2023 to USD 9.00 billion by 2030, exhibiting a CAGR of 7.8% during the forecast period.

There has been a strong and sustained increase in demand for cosmetic procedures in the current scenario, especially non-invasive cosmetic procedures such as dermal fillers. These are gel-like substances injected beneath the skin of the face to achieve an aesthetic outcome. Some of the dermal filler applications are facial line correction, wrinkle correction, restoration of lost volume, lip enhancement, and acne scars. As disposable income across the globe, especially in emerging regions, increases, these procedures are expected to boost procedural volumes. Furthermore, the increasing awareness regarding filler procedures has significantly reduced the taboos associated with cosmetic procedures. Such changes in attitudes are expected to significantly lead to the adoption of these products. 

In response to these positive trends of market growth, several companies engaged in manufacturing facial injectables have invested considerably in R&D initiatives. These R&D initiatives have led to the development of a considerable number of products with significantly improved aesthetic outcomes. Such product launches are also expected to strongly contribute to the growth of the market in the forecast period. The global market is expected to gain strong growth during forecast period owing to the greater demand for aesthetic procedures coupled with new product launches with a wide range of applications.

COVID-19 IMPACT

Cancellation of Elective Cosmetic Procedures Negatively Impacted the Market amid COVID-19

The impact of COVID-19 was visible in the healthcare sector, as it was at the epicenter of this unprecedented global pandemic challenge. The market has been particularly impacted as it is considered an elective procedure and was among the first medical procedures to be hit by cancellations. Major companies witnessed a decline in their revenue in 2020 compared to the previous year as elective and non-essential procedures were significantly delayed in several countries. For instance, the global revenue of Juvederm was reduced by 40.2% in 2020 compared to the previous year. The product earned a revenue of USD 718.0 million in 2020, which is comparatively much less than its 2019 revenue, i.e., USD 1,243.7 million. Due to the COVID-19 imposed lockdowns, the medical cosmetics sector witnessed disruptions in supply chains due to limitations on import and export, flight closures, reduced production, and disturbed supply channels. Furthermore, in terms of the procedure volume statistics released by the International Society of Aesthetic Plastic Surgery (ISAPS) in 2020, there was an overall global decrease in nonsurgical procedures such as botulinum toxin and hyaluronic acid. These procedures witnessed a decline of 0.9% and 6.1%, respectively. However, in 2021, the nonsurgical procedures such as botulinum toxin and hyaluronic acid were increased to 30.3% and 17.7%, respectively. This instance showed the decline in product demand during FY 2020, which eventually affected the growth of the market.

In 2021, the global market recovered from the pandemic as the world slowly witnessed a relaxation in the COVID-19 guidelines due to decline in the number of positive cases. Major companies, such as AbbVie Inc. and Revance Therapeutics, witnessed a growth in their aesthetics portfolio as a surge in demand for injectable treatments was witnessed globally. For instance, Revance Therapeutics accounted for USD 70.8 million in 2021 for their RHA collection of dermal fillers compared to USD 12.9 million in the year 2020. Similarly, due to increase in brand investment and strong recovery from COVID-19, AbbVie Inc. also witnessed an increase of 113.7% in their revenue earned by the sale of Juvederm globally compared to 2020. Such factors have diverted the market to the pre-pandemic growth level in the forecast period.

LATEST TRENDS

Request a Free sample to learn more about this report.

Rising Adoption of Injectable Fillers among Male Population 

One of the most prevalent trends witnessed in the global market is that almost all the demographic groups have shown inclination toward or interest in these non-invasive or minimally invasive procedures. This is particularly relevant for the male demographic group, which has increasingly adopted these procedures to enhance their appearances. For instance, an increasing number of men find that age and gravity can negatively impact the appearance of their facial features. Hence, facial fillers treatments are adopted by males for their effectiveness in reversing the early gravitational aging that occurs in the face. Furthermore, it provides the added advantage of no downtime needed for the recovery.

According to the ISAPS Global Survey Results, 2021, the male demographic group opting for hyaluronic acid procedures accounted for approximately 11.1% of the total global non-surgical procedures. With greater attention being paid to this demographic group by dermatologists, this proportion may increase over the forecast period. Hence, these new trends are expected to open up a new patient population base for the companies engaged in the global market and are expected to significantly contribute to the market’s growth during the forecast period.

DRIVING FACTORS

Surge in Demand for Minimally Invasive Cosmetic Procedures to Boost Market Expansion

One of the most critical market drivers for the global dermal fillers market growth is the substantial increase in demand for facial aesthetics. Individuals have sought easier and comparatively painless procedures for a youthful appearance and healthy visage in recent times. Since invasive cosmetic surgeries often have a number of risks attached and often necessitate the patient to take additional days for recovery from the surgery. According to the American Society of Plastic Surgeons 2020 report, approximately 13.2 million cosmetic procedures were carried out in the U.S., out of which 3.4 million were for soft tissue fillers. Such strong statistics further illustrate the significant increase in the demand for aesthetic procedures.

The surge in demand for these types of aesthetic procedures has also positively impacted the manufacturers of filler products. Various companies engaged in aesthetics are increasingly launching products to meet the growing demand for medical aesthetics. For instance, in May 2020, Galderma received approval from the U.S. Food and Drug Administration for Restylane Kysse. The product is approved for adults over the age of 21 with an indication for lip augmentation and correction of upper perioral rhytides (wrinkles around upper lips). Such launches are also anticipated to lead to increased demand for these procedures due to increased awareness.

Increasing R&D Initiatives Coupled with Rising Demand for Dermal Filler Procedures to Augment Market Growth

One of the other most critical drivers of the global market is the increasing number of R&D initiatives for the development of new fillers. These products have a wide range of aesthetic indications. The growth in the number of application areas in various non-invasive or minimally invasive cosmetic procedures is anticipated to drive market growth. Furthermore, the large number of clinical trials as part of various R&D initiatives also positively contribute to market growth. For instance, in November 2021, Silk Medical Aesthetics and Evolved by Nature announced positive results for their 44 patients’ feasibility study under an FDA approved Investigational Device Exemption (IDE) clinical trial. The trial was conducted for their all-natural dermal filler for nasolabial folds (NLFs). The ABOUT FACE BY NATURE dermal filler is said to be biocompatible and biodegradable.

Furthermore, the positive growth trends in the number of dermal fillers procedures over the years also contributed to the growth of the market during the forecast period. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2021, an estimated 5,279,344 procedures involving hyaluronic acid fillers were conducted worldwide. This represented an increase of 30.3% over the previous year, 2020. Such a strong volume increase in the number of aesthetic procedures is also expected to further contribute to market growth in the forecast period.

RESTRAINING FACTORS

High Costs and Relative Side Effects of Product to Hinder Market Growth 

Despite various aesthetic applications, several limiting factors are projected to restrain the global market’s growth during the forecast period. The high cost associated with these products is one of the major hindrances contributing to the decline of the growth of the global market. The cost of the dermal filler may depend on factors such as the expertise and qualifications of the person performing the treatment, the type of procedure used, and the time and effort the procedure or treatment requires. Furthermore, the non-permanent nature of these products may require the person to opt for repeated aesthetic treatments. This, in turn, increases the financial burden on the individual, and they may not opt for these elective procedures.

In addition, the harmful effects caused by the administration of such filler injections are another major factor contributing to the decline in the growth of the market. The possible adverse effects include pain, swelling, or bruising at the injection site'; redness; bruising; infections; and lumps & bumps. Besides, sometimes, a few adverse reactions, such as vision loss and severe scarring, are experienced in person due to accidentally injecting fillers into blood vessels. Hence, these factors mentioned above can restrict the market’s growth during the forecast period.

SEGMENTATION

By Material Analysis

To know how our report can help streamline your business, Speak to Analyst

Hyaluronic Acid Segment to Grow at Faster Pace in 2023-2030 As It is a Gold Standard For Fillers

Based on material, the global market is segmented into hyaluronic acid, calcium hydroxylapatite, Poly-L-Lactic Acid (PLLA), PMMA (poly (Methyl Methacrylate)), fat fillers, and others.

The hyaluronic acid (HA) segment emerged as the dominant segment in 2022, owing to its status as a gold standard for fillers. Furthermore, new product launches in this segment are positively driving the segment’s growth. The increase in the demand for hyaluronic acid-based products is primarily driven by their safety and comparative longevity. Furthermore, key companies launching hyaluronic acid products in high-growth countries such as the U.S. and U.K. are expected to drive the segment’s growth during the forecast period.

• In February 2021, Merz Aesthetics announced the U.S. launch of BELOTERO BALANCE (+), an injectable hyaluronic acid filler with lidocaine.

The calcium hydroxylapatite segment held the second-highest market share in 2022, owing to its safety features. Furthermore, the launch of new products in this segment by key players also drives the growth of the segment. For instance, in April 2022, Allergan Aesthetics launched HArmonyCa with Lidocaine. The injectable dermal filler has two active ingredients: calcium hydroxylapatite (CaHA) for sustained collagen stimulation and hyaluronic acid for immediate lift. The fat fillers segment is projected to expand with a robust CAGR during the forecast period, owing to the rise in the number of fat filler procedures in key regions such as North America.

The PMMA (Poly (Methyl Methacrylate)) segment accounted for a lower market share owing to the decreased adoption rates of these products due to their non-biodegradable nature. The Poly-L-lactic Acid segment is anticipated to witness growth trends due to trends such as product re-launches.

By Product Analysis

Strong Presence of Biodegradable Products in Market to Enable Segment’s Dominance

On the basis of product, the market is segmented into biodegradable and non-biodegradable.

The biodegradable segment is anticipated to hold the highest market share in the forecast period. The higher share of the segment is attributed to the larger availability of product offerings in this segment as compared to non-biodegradables and the wider aesthetic applications of biodegradable products. The greater degree of safety and strong regulatory approval for the products and the current R&D initiatives of major and emerging players to introduce new products in the biodegradable segment are also expected to contribute to the segment’s growth. For instance, in March 2022, Hallura Ltd., an aesthetic company based in Israel, announced that they had received successful topline results for their next generation hyaluronic acid dermal filler with their proprietary BiOLinkMatrix platform during their multi-site European clinical trial. The safety and effectiveness of the dermal filler are being tested for three indications: lip enhancement, nasolabial folds’ correction and cheek enhancement.

The non-biodegradable segment accounted for a lower market share in 2022, owing to the non-temporary nature of these products, which resulted in considerably lower adoption rates. In contrast to temporary and semi-permanent fillers, non-biodegradable products are not decomposable and remain in the body for a longer time.

By Application Analysis

Wrinkle Correction Dominated in 2022 Due to High Demand 

On the basis of application, the global market is segmented into scar treatment, wrinkle correction treatment, lip enhancement, restoration of volume/fullness, and others.

In terms of the application segment, the wrinkle correction segment accounted as the leading segment due to greater demand for these types of procedures. Furthermore, new product launches directed at this segment are anticipated to lead to the segment’s growth. In January 2022, the U.S. FDA approved Teoxane’s RHA Redensity, which can be used to reduce the appearance of facial lines and wrinkles.

The lip enhancement segment accounted for the second-largest segment due to the strong volume of lip procedures. The rising demand for aesthetic improvements for the lips, driven by the development of minimally-invasive procedures, is expected to drive the segment. For instance, in April 2018, Merz Pharma announced the launch of Belotero Lips, which is specifically manufactured for the purpose of lip enhancement and the treatment of perioral lines.

The restoration of the volume/fullness segment is anticipated to account for the third-largest segment owing to product launches such as Allergan’s (AbbVie, Inc.) JUVEDERM VOLUX. The scar treatment is expected to account for a comparatively lower market share in the forecast period.

By End-user Analysis

Specialty & Dermatology Clinics to Grow at Highest CAGR during 2023-2030

Based on end-user, the market is segmented into specialty & dermatology clinics, hospitals & clinics, and others.

The specialty & dermatology clinics segment is expected to be the dominant segment during the forecast period. The segment's dominance is attributed to the large volume of cosmetic procedures conducted in specialty and dermatological clinics. This is the major factor driving the growth of the segment. Also, the growing collaboration of clinics with stores to enhance product availability is contributing to the segment’s expansion.

• In June 2022, CAVENDISH CLINIC partnered with John Lewis Plc to provide aesthetic and beauty treatments, including these fillers. CAVENDISH CLINIC will provide its services in John Lewis stores across the U.K. Furthermore, as aesthetic procedures such as wrinkle correction do not require a hospital stay, these factors are expected to support the segment’s growth.

The hospitals & clinics segment accounted for the second-highest market share in 2022, owing to the robust number of aesthetic procedures such as facial injectable conducted in hospitals and clinics. The others segment is expected to witness a comparatively lower market growth rate and market revenue share in the forecast period.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

On the basis of region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The North America dermal filler market size was valued at USD 2.10 billion in 2022. The region is expected to account for the dominant share of the global market during the forecast period. Some of the reasons for the dominance of this region include a highly aware and economically stable population, coupled with a comparatively higher number of cosmetic procedures performed in the region. For instance, according to the American Society of Plastic Surgeons (ASPS), in 2020, about 15.6 million cosmetic procedures were performed in the U.S. Furthermore, regulatory approvals and new product launches are also expected to drive the region’s growth in the forecast period. For example, according to the International Academy of Facial Aesthetics, in August 2020, Revance Aesthetics announced the launch of resilient hyaluronic acid (RHA) dermal fillers in the U.S. market.

Europe is anticipated to hold the second highest market share in 2022, which is attributable to the increasing preference amongst individuals for undergoing dermal filler procedures in key European countries and rising expenditure on R&D in Europe. For instance, according to the ISAPS Global Survey Results 2021, in Germany, approximately 254,743 hyaluronic acid procedures were performed, making it one of the key countries in Europe with the highest number of cosmetic procedures.

Asia Pacific is estimated to witness the highest growth rate during the forecast period. The improvement in healthcare infrastructure in Asian countries, the growing aging population, and the increasing consciousness of individuals regarding their physical appearance are driving market growth in the region. Furthermore, the efforts of major players to launch their products in the major countries of Asia Pacific fuel the market’s growth. For instance, in April 2020, Galderma announced that it received three new approvals from the National Medical Products Administration of China (NMPA) for Restylane Vital, Restylane Lidocaine, and Restylane Lyft Lidocaine. This initiative expands Restylane’s portfolio in China. Such developments are expected to further contribute to the strong growth of the region.

Latin America and the Middle East & Africa accounted for a relatively lesser market share in the forecast period. However, developing healthcare infrastructure in these countries and the rising influx of players with novel products in these regions can be pivotal in driving the growth of the market in these countries in the future during the forecast period. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2021, the total number of hyaluronic acid procedures performed in Turkey was 192,023.

KEY INDUSTRY PLAYERS

Robust Portfolio of ALLERGAN (AbbVie, Inc.) to Elevate the Company to a Dominant Position

In terms of the competitive landscape, the market has diverse players, with companies ranging from large, established players to small, emerging players. In terms of the present market scenario, ALLERGAN (AbbVie, Inc.) dominates the market, accounting for a substantial proportion of the global dermal fillers market’s revenue. The company dominates the market due to its strong product portfolio, which includes the JUVEDERM Collection of Hyaluronic Acid (HA) fillers. Furthermore, the diverse application areas of the JUVEDERM Collection also further cement the company’s peak position in the global market.

However, companies, such as Revance Therapeutics, Inc., and Merz Pharma are engaged in strategic movements such as new product launches and collaborations to further strengthen their market presence. In addition, other prominent players, such as Galderma and Sinclair Pharma, are focusing on new product launches in key regions to increase their market revenue share in the global market.

LIST OF KEY COMPANIES PROFILED:

• ALLERGAN (AbbVie, Inc.) (U.S.)


• Revance Therapeutics, Inc. (U.S.)


• Merz Pharma (Germany)


• Galderma (Switzerland)


• Sinclair Pharma (U.K.)


• BIOPLUS CO., LTD. (South Korea)


• Bioxis Pharmaceuticals (France)


• SCULPT Luxury Dermal Fillers Ltd. (Czech Republic)


• DR. Korman (Israel)


• Prollenium Medical Technologies (Canada)


• Suneva Medical (U.S.)


• Anika Therapeutics, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• January 2023: ALLERGAN (AbbVie, Inc.) launched JUVÉDERM VOLUX XC to treat moderate to severe loss of jawline definition in adults over the age of 21.


• October 2022: Prollenium Medical Technologies acquired SoftFil medical devices with the aim to innovate powerful tools for practitioners and patients with optimal results.


• February 2022: Galderma launched Radiesse (+) Lidocaine injectable implants for deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation. It improves moderate to severe loss of jawline contour in adults over the age of 21.


• March 2021: Galderma announced the re-launch of Sculptra (injectable poly-L-lactic acid) in Europe with an updated administration protocol.


• February 2021: Allergan Aesthetica and CollPlant announced a development and global commercial agreement to use their plant derived recombinant human collagen (rhCollagen) with Allergan’s proprietary technology to develop and commercialize dermal and soft tissue fillers.

REPORT COVERAGE

An Infographic Representation of Dermal Fillers Market

View Full Infographic

To get information on various segments, share your queries with us

The global market research report provides market segmentation, size and growth rate. It includes a detailed global dermal fillers market analysis and focuses on key aspects such as the overview of the product types, regulatory scenario by key countries, reimbursement scenario by key countries, and pipeline analysis. Additionally, it includes an overview of new product launches/approvals and the impact of COVID-19 on the market. In addition, the report offers insights into market trends and highlights key strategies by market players. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation